10 Sep 2025
🧬Prospective Exclusive Patent License for Cancer Treatment Innovations
Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers
Summary
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an NCI Exclusive Patent License to practice the inventions embodied in the patents listed in the Supplementary Information section of this notice to Lysin Therapeutics, Inc. (Lysin), a company located in Silver Spring, MD.
Agencies
- Health and Human Services Department
- National Institutes of Health
Business Impact
$$$ - High
This notice pertains to the prospective exclusive patent license for technologies relevant to cancer treatments, which may present significant opportunities for businesses in the biomedical and pharmaceutical sectors. The outlined inventions could lead to new product development and grant funding opportunities for eligible companies.